April 27, 2020 09:10 AM EDTUpdated 11:31 AM
R&D

#AACR20: Ear­ly da­ta sug­gest No­var­tis' In­cyte-dis­cov­ered MET in­hibitor helps lung can­cer pa­tients with brain le­sions

Natalie Grover

Reporter

Months af­ter cap­ma­tinib — the MET in­hibitor de­signed to cross the blood-brain bar­ri­er dis­cov­ered by In­cyte and li­censed by No­var­tis — se­cured the FDA’s pri­or­i­ty re­view …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

In sur­prise move, FDA's No. 2 Bum­pus to leave agency at end of 2024

Tessera gets up to $50M from the Gates Foun­da­tion; Tvar­di’s re­verse merg­er

Ex­clu­sive: In­sitro makes head­way on the hard­er road, dis­cov­er­ing new ALS drug tar­get

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

A service from the Financial Times